Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Key facts
- Where
- Aachen, Bad Bentheim, Berlin, Bochum, Buxtehude, Darmstadt, Dortmund, Dresden, Duesseldorf, Erlangen, Frankfurt Am Main, Goettingen, Hamburg, Hannover, Heidelberg, Kiel, Leipzig, Luebeck, Magdeburg, Mainz, Merzig, Muenster, Munich, Oldenburg, Tuebingen, and Witten, GermanySee the 28 sites
- Phase
- Phase 3
Where in Germany
- Universitaetsklinikum Aachen AöRAachen, GermanyTaking people
- Thermalsole und Schwefelbad Bentheim GmbHBad Bentheim, GermanyTaking people
- Charite Universitaetsmedizin Berlin KöRBerlin, GermanyTaking people
- Hautzentrum Friedrichshain StudienBerlin, GermanyTaking people
- Katholisches Klinikum Bochum gGmbHBochum, GermanyTaking people
- Elbe Kliniken Stade-Buxtehude gGmbHBuxtehude, GermanyTaking people
- Klinikum Darmstadt GmbHDarmstadt, GermanyTaking people
- Rosenpark Research GmbhDarmstadt, GermanyTaking people
- Klinikum Dortmund gGmbHDortmund, GermanyTaking people
- Universitaetsklinikum Carl Gustav Carus Dresden an der Technischen Universitaet Dresden AöRDresden, GermanyTaking people
- Universitaetsklinikum Duesseldorf AöRDuesseldorf, GermanyTaking people
- Universitaetsklinikum Erlangen AöRErlangen, GermanyTaking people
- Goethe University FrankfurtFrankfurt Am Main, GermanyTaking people
- Universitaetsmedizin GoettingenGoettingen, GermanyTaking people
- University Medical Center Hamburg-EppendorfHamburg, GermanyTaking people
- Hautaerzte Zentrum HannoverHannover, GermanyTaking people
- Universitaetsklinikum Heidelberg AöRHeidelberg, GermanyTaking people
- Universitaetsklinikum Schleswig-Holstein AöRKiel, GermanyTaking people
- Universitaet LeipzigLeipzig, GermanyTaking people
- Universitaetsklinikum Schleswig-Holstein AöRLuebeck, GermanyTaking people
- Magdeburger Company For Medical Studies & Services GmbHMagdeburg, GermanyTaking people
- BAG Dres. med. Quist PartGMainz, GermanyTaking people
- Hms GmbHMerzig, GermanyTaking people
- Universitatsklinikum Munster AöRMuenster, GermanyTaking people
- Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)Munich, GermanyTaking people
- Klinikum Oldenburg AorOldenburg, GermanyTaking people
- Universitaetsklinikum Tuebingen AöRTuebingen, GermanyTaking people
- Hautarztpraxis Dr. med. Matthias HoffmannWitten, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Incyte Corporation
- Trial code
- NCT06855498EU 2024-520107-12-00
- Record updated
- 30 October 2026
- Original description
Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.Read full original descriptionShow less
A Phase 3b, Multicenter, Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.
Inclusion: Ability to comprehend and willingness to sign a written ICF for the study; Completed the treatment period of a predetermined, Incyte-sponsored, povorcitinib parent study without safety or tolerability concerns, per investigator's assessment; Received clinical benefit from treatment with study drug during the parent study, as determined by the investigator; Demonstrated compliance, as assessed by the investigator, with the parent Protocol requirements; Willingness to avoid pregnancy or fathering children as defined in the protocol; Willingness and ability to comply with the study Protocol and procedures.
Exclusion: Had temporary study drug interruption due to safety and/or efficacy reasons at or after the final visit of the parent study; Received at least 1 dose of either of the following therapies within the 28 days prior to starting treatment in this rollover study:; Biologic immunomodulator (examples include but are not limited to adalimumab, bimekizumab, dupilumab, infliximab, nemolizumab, secukinumab); Live, attenuated vaccine; Plans for administration of a live, attenuated vaccine during this study or within 8 weeks after the last dose of study drug; Currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study; Known hypersensitivity or severe reaction to povorcitinib or excipients of povorcitinib and/or other products in the same class; Any condition that would, in the investigator's and/or sponsor's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data; Other protocol-defined Inclusion/Exclusion Criteria may apply; Had been permanently discontinued from study treatment during the parent study; Women who are pregnant (or who are considering pregnancy) or breastfeeding.